Navigation Links
Par Pharmaceutical Companies Reports First Quarter 2012 Results

WOODCLIFF LAKE, N.J., May 8, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the first quarter ended March 31, 2012.

For the first quarter ended March 31, 2012, the Company reported total revenues of $271.5 million and a loss from continuing operations of $28.7 million, or $0.79 per diluted share, which includes a $45 million charge related to the Company's best estimate of loss related to the potential settlement of the on-going Department of Justice investigation of Strativa's marketing of Megace® ES. On an adjusted cash basis (non-GAAP measure), which excludes the $45 million charge, a milestone payment, amortization expenses, other transaction-related costs and the impairment of an IPR&D asset, income from continuing operations was $29.8 million, or $0.80 per diluted share for the first quarter 2012.  (Refer to attached reconciliation table between GAAP and adjusted non-GAAP amounts.)

First Quarter Highlights  Key Product Sales (Net sales comparisons at the product level are to fourth quarter 2011.)

  • Metoprolol:  For the quarter ended March 31, 2012, net sales of metoprolol succinate were $61.8 million compared to $56.4 million in the fourth quarter 2011.  The increase was driven by customer buying patterns.  Par Pharmaceutical, the Company's generic drug division, is the authorized generic for all strengths of AstraZeneca's Toprol XL®.
  • Budesonide EC:  Net sales for budesonide EC in the first quarter 2012 were $38.0 million compared to $33.1 million in the fourth quarter 2011.  The increase was driven by customer buying patterns.  Par Pharmaceutical is the authorized generic for AstraZeneca's Entocort® EC.
  • Propafenone Hydrochloride ER: Net sales for propafenone hydrochloride ER in the first quarter were $19.1 million compared to $16.4 million in the fourth quarter 2011.  Par Pharmaceutical remained the exclusive supplier of generic Rythmol SR® throughout the first quarter.
  • Sumatriptan: Net sales of sumatriptan succinate were $16.7 million in the first quarter compared to $15.3 million in the prior quarter.  The increase was driven by customer buying patterns in advance of our expected second half 2012 exit from this product.
  • Bupropion Hydrochloride ER: Net sales of bupropion were $11.4 million in the first quarter 2012.  Par recorded $6.1 million of net sales in the last six weeks of the fourth quarter following the closing of its acquisition of Anchen Pharmaceuticals.
  • Zolpidem Tartrate: Net sales of zolpidem tartrate of $6.9 million in the first quarter 2012.  Par recorded $5.3 million of net sales in the last six weeks of the fourth quarter following the completion of the Anchen acquisition.
  • Fentanyl Citrate Lozenges: Net sales for fentanyl for the first quarter were $2.0 million compared to $2.6 million in the fourth quarter.  The decrease is due to customer buying patterns.
  • Other Generic Products:  For the first quarter 2012, net sales from all other generic products were $95.3 million. This compares to fourth quarter 2011 net sales of $91.8 million.  The increase is due to product mix and a full quarter of Anchen products.
  • Megace® ES:  Net sales were $12.2 million for the first quarter compared to $15.8 million in the fourth quarter.  The decrease was due to customer buying patterns.  
  • Nascobal® B12 Nasal Spray:  Net sales were $5.9 million for the first quarter compared to $6.6 million in the fourth quarter 2011.  The decrease was due to lower prescription volume.
  • Revenues and adjusted gross margin for the first quarter 2012 were $271.5 million and $110.7 million, respectively, compared to $253.6 million in net sales and $103.8 million in adjusted gross margin during the prior quarter (Q4 2011). The adjusted gross margin rate on the Company's consolidated product portfolio remained essentially flat at 40.8% versus 40.9% in the fourth quarter 2011.  (Par is now presenting non-GAAP gross margin on an adjusted basis. See detailed reconciliation table at the end of this press release.) 1Q 20124Q 2011$%$%Key Par (Generic)

    Products (1)$   46.4

    29.8%$   35.4

    26.2%All Other (Generic)47.8


    50.5%Total Par Generics$   94.2

    37.5%$   81.8

    36.0%Strativa (Branded) Products(2)$   16.5

    81.5%$   22.0

    82.4%Total (All Products) $ 110.7

    40.8%$ 103.8

    40.9%(1) Q1 2012 Key Par Products include metoprolol, sumatriptan, budesonide, propafenone, bupropion,
    zolpidem, fentanyl lozenges.  (2) Strativa products consist primarily of Megace ES and Nascobal. 

    Operating Expenses
    On a GAAP basis, total operating expenses increased during the first quarter of 2012 as compared to the prior quarter as follows:

  • Research and development expenses were $29.9 million in the first quarter 2012 compared to $18.1 million in the fourth quarter 2011.  The increase was due primarily to a one-time upfront development payment, as well as a full quarter of Anchen research and development expenses and a partial quarter of Edict Pharmaceuticals research and development expenses following Par's acquisition of Edict.
  • Selling, general and administrative expenses for the first quarter 2012 decreased to $42.2 million compared to $44.5 million in the fourth quarter of 2011.  The decrease reflects significantly lower transaction-related costs tempered by a full quarter of Anchen expenses.
  • Cash and cash equivalents and marketable securities aggregate balance as of March 31, 2012 was $186.5 million, which included a payment of $25.0 million in conjunction with the Edict acquisition and a one-time upfront development payment.

    Product and Pipeline Update In February 2012, Par Pharmaceutical, Inc. completed its acquisition of privately-held Edict Pharmaceuticals Private Limited, an India-based developer and manufacturer of generic pharmaceuticals.  Edict has been renamed Par Formulations Private Limited.

    In April 2012, Par Pharmaceutical, Inc. announced that it had entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals LLC to acquire Handa's ANDA for dexlansoprazole capsules, the generic version of Takeda's Dexilant®.  Under the terms of the agreement, Par has the exclusive rights to market, sell and distribute dexlansoprazole capsules in the U.S. under the ANDA, subject to final FDA approval.  Par will receive a percentage of profits from the sales of the product.  Handa believes it is the first to file an ANDA containing a paragraph IV certification for the 60 mg strength of the product, which would potentially provide 180 days of marketing exclusivity.  According to IMS Health data, annual sales in the U.S. for the 60 mg strength of Dexilant are approximately $517 million.

    Par Pharmaceutical, along with third-party partners, currently has approximately 71 ANDAs pending with the FDA, 21 of which it believes to be first-to-file opportunities.

    Conference Call Par Pharmaceutical Companies, Inc. will host a conference call and live webcast on Tuesday, May 8, 2012 at 9:00 AM EDT to review results for the first quarter 2012. 

    Access to the live webcast can be made via the Company's website at InformationDomestic:800-510-0146International:617-614-3449Passcode: 

    72245227A replay of the conference call will be available for two weeks approximately one hour after the call.  Replay InformationDomestic:888-286-8010International:617-801-6888Passcode:42736584Non-GAAP MeasuresPar Pharmaceutical Companies, Inc. ("the Company") believes it prepared its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission.  In an effort to provide investors with additional information regarding the Company's results and to provide a meaningful period-over-period comparison of the Company's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission.  The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in attached schedules.  In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating the Company's underlying business performance.  Management uses the non-GAAP financial measures to evaluate the Company's financial performance against internal budgets and targets.  In addition, management internally reviews the Company's results excluding the impact of certain items, as it believes that these non-GAAP financial measures are useful for evaluating the Company's core operating results and facilitating comparison across reporting periods.  Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures.  The Company's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

    About Par Pharmaceutical Companies, Inc.Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company.  Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, acquires, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit

    Safe Harbor StatementCertain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

     PAR PHARMACEUTICAL COMPANIES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Share and Per Share Data)(Unaudited)March 31,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents$156,876$162,516Available for sale marketable debt securities29,63025,709Accounts receivable, net  135,200125,940Inventories92,796106,250Prepaid expenses and other current assets26,20820,475Deferred income tax assets50,44555,966Income taxes receivable31,14627,049Total current assets522,301523,905Property, plant and equipment, net102,03997,790Intangible assets, net302,317311,669Goodwill313,337283,432Other assets14,28614,657Total assets$1,254,280$1,231,453LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Current portion of long-term debt$26,250$21,875Accounts payable31,53633,000Payables due to distribution agreement partners73,20369,359Accrued salaries and employee benefits 13,27016,174Accrued government pricing liabilities27,98939,614Accrued legal fees6,6454,150Accrued legal settlements82,80037,800Payable to former Anchen securityholders20,59820,620Accrued expenses and other current liabilities18,8069,604Total current liabilities301,097252,196Long-term liabilities23,48119,952Non-current deferred tax liabilities26,93925,974Long-term debt, less current portion315,000323,750Commitments and contingencies--Stockholders' equity:Common stock, par value $0.01 per share, authorized 90,000,000 shares; issued39,919,972 and 39,677,291 shares399397Additional paid-in capital398,085389,166Retained earnings274,261302,984Accumulated other comprehensive income4813Treasury stock, at cost 3,247,206 and 3,201,858 shares(85,030)(82,979)Total stockholders' equity587,763609,581Total liabilities and stockholders' equity$1,254,280$1,231,453 

     PAR PHARMACEUTICAL COMPANIES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Data)(Unaudited)Three months endedMarch 31,March 31,20122011Revenues:Net product sales

    $264,123$220,789Other product related revenues

    7,34912,163Total revenues

    271,472232,952Cost of goods sold, excluding amortization expense

    164,804120,539Amortization expense

    8,8222,761Total cost of goods sold

    173,626123,300Gross margin

    97,846109,652Operating expenses:Research and development

    29,90010,710Selling, general and administrative

    42,15946,945Intangible assets impairment

    2,000-Settlements and loss contingencies, net

    45,000190,560Total operating expenses

    119,059248,215Operating loss

    (21,213)(138,563)Interest income

    136423Interest expense

    (3,094)(150)Loss from continuing operations before
    provision (benefit) for income taxes

    (24,171)(138,290)Provision (benefit) for income taxes

    4,525(29,446)Loss from continuing operations

    (28,696)(108,844)Discontinued operations:Provision for income taxes

    27127Loss from discontinued operations

    (27)(127)Net loss

    ($28,723)($108,971)Basic loss per share of common stock:Loss from continuing operations

    ($0.79)($3.07)Loss from discontinued operations

    (0.00)(0.00)Net loss

    ($0.79)($3.07)Diluted loss per share of common stock:Loss from continuing operations

    ($0.79)($3.07)Loss from discontinued operations

    (0.00)(0.00)Net loss

    ($0.79)($3.07)Weighted average number of common shares
    outstanding:  Basic

    36,30535,500  Diluted

    36,30535,500 Reconciliation Between Reported (GAAP); Adjusted Income (Loss) from Continuing Operations and "Cash EPS"(In Thousands, Except Per Share Data)(Unaudited)

    Three Months EndedMarch 31, 2012

    GAAP 10-Q P&L

    $264,123$264,123Other product related revenues

    7,3497,349Total revenues

    271,472271,472Cost of goods sold, excluding amortization expense




    Amortization expense




    Total cost of goods sold

    173,626(12,870)160,756Gross margin

    Gross margin %

    36%41%Operating expenses:Research and development




    Selling, general and administrative




    Intangible assets impairment




    Settlements and loss contingencies, net




    Total operating expenses

    119,059(59,302)59,757Operating (loss) income

    (21,213)72,17250,959Interest income

    136136Interest expense

    (3,094)(3,094)(Loss) income from continuing operations before
    provision for income taxes

    (24,171)72,17248,001Provision for income taxes



    18,222(Loss) income from continuing operations(28,696)58,47529,779Discontinued operations:Provision (benefit) for income taxes27(27)-(Loss) income from discontinued operations(27)27-Net (loss) income($28,723)$58,502$29,779Basic earnings per share of common stock:(Loss) income from continuing operations($0.79)$0.82(Loss) income from discontinued operations(0.00)0.00Net (loss) income($0.79)$0.82Diluted earnings per share of common stock:(Loss) income from continuing operations($0.79)$0.80(Loss) income from discontinued operations(0.00)0.00Net (loss) income($0.79)$0.80Weighted average number of common shares
    outstanding:  Basic36,30536,305  Diluted36,30537,051 

    a - Amortization of inventory step up established with Anchen purchase accounting ($4,048)b - Amortization expense ($8,822)c - Upfront and development milestone paymentsd - Transaction costs on Anchen ($772)/Edict ($676), amortization expense for Megace ($380), and Anchen-related severance costs ($474)e - Impairment of Anchen IPR&D intangible assetsf -  Contingent lossg -  Estimated tax on adjustments ($13,697) 


    SOURCE Par Pharmaceutical Companies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    (Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
    (Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
    (Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
    (Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
    (Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
    (Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
    Breaking Medicine News(10 mins):